Why Wall Street Is Excited about Alexion Pharmaceuticals

The fourth-quarter update from Alexion Pharmaceuticals, Inc. led to upgrades from Wall Street. Here's why.

Feb 7, 2014 at 6:30PM

Investors seem pretty excited about Alexion Pharmaceuticals (NASDAQ:ALXN), which saw shares rocket up 20% after announcing fourth quarter earnings. Interestingly, the fourth quarter saw a loss of $0.10 per share due to restructuring costs (mainly from centralizing a number of its operations) and some impairment charges, although excluding these one-off charges meant the company made a profit of $0.87 per share for the fourth quarter.

However, despite making a loss including one-off charges, shares in Alexion made those gains after the release due to the company raising its own forecasts for sales of its Soliris drug. Alexion now expects more than $2 billion in annual revenue for Soliris -- considerably higher than the $1.5 billion that was delivered in 2013 and even higher than market forecasts for 2014 of $1.9 billion.

One reason for the increases in sales forecasts for Soliris is multiple marketing approvals that Alexion hopes to achieve for the drug. This process began in 2007 when Soliris was approved as an orphan treatment for a life-threatening condition called paroxysmal nocturnal hemoglobinuria, which causes a breakdown of red blood cells and can lead to organ failure. The process continued in 2011 when Soliris was approved as an orphan treatment for atypical hemolytic uremic syndrome, which can lead to kidney failure and death.

The seeking of further marketing approvals continues and just last month Soliris was approved as an orphan treatment for the prevention of delayed graft function, which can be a complication for kidney transplant patients. However, the process is unlikely to end there as Alexion looks set to continue to gain additional marketing approvals for the drug in the future.

Meanwhile, biotechnology sector peer Amgen (NASDAQ:AMGN) also delivered strong performance in its product portfolio in the fourth quarter of 2013. Although the quarter signaled the end of the profit share in Enbrel, total product sales increased by 11% versus the fourth quarter of 2012, with the combined Neulasta and Neupogen sales increasing by 8% in the fourth quarter and for the full year.

While shares did not react strongly to the release, Amgen's guidance was roughly in line with consensus forecasts and should see earnings-per-share growth in the mid-to-high single digits during 2014 and 2015.

Similarly, Gilead Sciences (NASDAQ:GILD) beat fourth quarter expectations when it posted a 4% increase in quarterly profit. However, of greater interest to the market could have been the progress on hepatitis C drug Sovaldi, which the company began marketing recently and which is expected to be a blockbuster drug.

Shares reacted favorably to the news and posted gains of around 4% immediately following the release, before falling to erase those gains. Still, shares are up 88% over the last year and, with the progress being made on marketing Sovaldi, 2014 could be an exciting year for Gilead.

Indeed, with Alexion upgrading its own forecasts for sales of Soliris, Amgen having a relatively diverse range of products that look set to deliver growth, and Gilead continuing with the process of marketing new drug Sovaldi, 2014 could be an interesting year for investors in the three companies.

The Motley Fool's top stock for 2014
There's a huge difference between a good stock and a stock that can make you rich. The Motley Fool's chief investment officer has selected his No. 1 stock for 2014, and it's one of those stocks that could make you rich. You can find out which stock it is in the special free report "The Motley Fool's Top Stock for 2014." Just click here to access the report and find out the name of this under-the-radar company.

Peter Stephens has no position in any stocks mentioned. The Motley Fool recommends Gilead Sciences. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

1 Key Step to Get Rich

Our mission at The Motley Fool is to help the world invest better. Whether that’s helping people overcome their fear of stocks all the way to offering clear and successful guidance on complicated-sounding options trades, we can help.

Feb 1, 2016 at 4:54PM

To be perfectly clear, this is not a get-rich action that my Foolish colleagues and I came up with. But we wouldn't argue with the approach.

A 2015 Business Insider article titled, "11 websites to bookmark if you want to get rich" rated The Motley Fool as the #1 place online to get smarter about investing.

"The Motley Fool aims to build a strong investment community, which it does by providing a variety of resources: the website, books, a newspaper column, a radio [show], and [newsletters]," wrote (the clearly insightful and talented) money reporter Kathleen Elkins. "This site has something for every type of investor, from basic lessons for beginners to investing commentary on mutual funds, stock sectors, and value for the more advanced."

Our mission at The Motley Fool is to help the world invest better, so it's nice to receive that kind of recognition. It lets us know we're doing our job.

Whether that's helping the entirely uninitiated overcome their fear of stocks all the way to offering clear and successful guidance on complicated-sounding options trades, we want to provide our readers with a boost to the next step on their journey to financial independence.

Articles and beyond

As Business Insider wrote, there are a number of resources available from the Fool for investors of all levels and styles.

In addition to the dozens of free articles we publish every day on our website, I want to highlight two must-see spots in your tour of fool.com.

For the beginning investor

Investing can seem like a Big Deal to those who have yet to buy their first stock. Many investment professionals try to infuse the conversation with jargon in order to deter individual investors from tackling it on their own (and to justify their often sky-high fees).

But the individual investor can beat the market. The real secret to investing is that it doesn't take tons of money, endless hours, or super-secret formulas that only experts possess.

That's why we created a best-selling guide that walks investors-to-be through everything they need to know to get started. And because we're so dedicated to our mission, we've made that available for free.

If you're just starting out (or want to help out someone who is), go to www.fool.com/beginners, drop in your email address, and you'll be able to instantly access the quick-read guide ... for free.

For the listener

Whether it's on the stationary exercise bike or during my daily commute, I spend a lot of time going nowhere. But I've found a way to make that time benefit me.

The Motley Fool offers five podcasts that I refer to as "binge-worthy financial information."

Motley Fool Money features a team of our analysts discussing the week's top business and investing stories, interviews, and an inside look at the stocks on our radar. It's also featured on several dozen radio stations across the country.

The hosts of Motley Fool Answers challenge the conventional wisdom on life's biggest financial issues to reveal what you really need to know to make smart money moves.

David Gardner, co-founder of The Motley Fool, is among the most respected and trusted sources on investing. And he's the host of Rule Breaker Investing, in which he shares his insights into today's most innovative and disruptive companies ... and how to profit from them.

Market Foolery is our daily look at stocks in the news, as well as the top business and investing stories.

And Industry Focus offers a deeper dive into a specific industry and the stories making headlines. Healthcare, technology, energy, consumer goods, and other industries take turns in the spotlight.

They're all informative, entertaining, and eminently listenable ... and I don't say that simply because the hosts all sit within a Nerf-gun shot of my desk. Rule Breaker Investing and Answers contain timeless advice, so you might want to go back to the beginning with those. The other three take their cues from the market, so you'll want to listen to the most recent first. All are available at www.fool.com/podcasts.

But wait, there's more

The book and the podcasts – both free ... both awesome – also come with an ongoing benefit. If you download the book, or if you enter your email address in the magical box at the podcasts page, you'll get ongoing market coverage sent straight to your inbox.

Investor Insights is valuable and enjoyable coverage of everything from macroeconomic events to investing strategies to our analyst's travels around the world to find the next big thing. Also free.

Get the book. Listen to a podcast. Sign up for Investor Insights. I'm not saying that any of those things will make you rich ... but Business Insider seems to think so.

Compare Brokers